Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)2.27bn
- Net income in SEK735.57m
- Incorporated2004
- Employees285.00
- LocationCamurus ABRydbergs torg 4LUND 224 84SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioGaia AB | 1.54bn | 332.76m | 10.16bn | 242.00 | 31.34 | 7.94 | 28.41 | 6.60 | 3.29 | 3.29 | 15.21 | 12.99 | 0.847 | -- | -- | 6,356,066.00 | 18.32 | 15.48 | 20.63 | 16.86 | 73.37 | 73.12 | 21.63 | 26.35 | -- | -- | -- | 133.18 | 8.11 | 15.54 | -5.30 | 13.11 | -25.87 | 24.01 |
| Bonesupport Holding AB | 1.12bn | 151.92m | 11.66bn | 143.00 | 77.40 | 14.15 | 71.85 | 10.42 | 2.29 | 2.29 | 16.83 | 12.52 | 1.26 | 0.6205 | 6.26 | 8,811,984.00 | 17.06 | 5.14 | 20.11 | 6.31 | 92.61 | 91.40 | 13.57 | 5.59 | 3.92 | 19.36 | 0.0133 | 0.00 | 52.05 | 42.04 | -45.41 | -- | 5.71 | -- |
| Vimian Group AB | 4.52bn | 331.81m | 13.98bn | 1.20k | 42.15 | 1.88 | 18.70 | 3.09 | 0.6306 | 0.6306 | 8.60 | 14.11 | 0.383 | 1.67 | 7.56 | -- | 2.92 | 1.42 | 3.27 | 1.62 | 68.90 | 69.18 | 7.62 | 3.96 | 1.22 | 7.96 | 0.2519 | 0.00 | 13.42 | 42.94 | 74.59 | -9.36 | 21.97 | -- |
| Bavarian Nordic A/S | 9.81bn | 3.48bn | 22.13bn | 1.74k | 6.41 | 1.17 | 4.93 | 2.25 | 30.57 | 30.57 | 85.79 | 168.13 | 0.4732 | 1.34 | 6.08 | 4,274,910.00 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| Camurus AB | 2.27bn | 735.57m | 30.84bn | 285.00 | 42.03 | 7.28 | 40.55 | 13.61 | 12.25 | 12.25 | 37.75 | 70.73 | 0.5332 | 1.24 | 5.36 | 7,948,695.00 | 17.31 | 14.26 | 19.13 | 16.65 | 93.11 | 91.95 | 32.47 | 21.07 | 11.78 | -- | 0.0244 | 0.00 | 21.30 | 46.47 | 71.70 | -- | 110.82 | -- |
| ALK-Abello A/S | 8.66bn | 1.57bn | 63.05bn | 2.76k | 43.89 | 7.84 | 31.38 | 7.28 | 4.98 | 4.98 | 27.51 | 27.86 | 0.7781 | 1.24 | 6.36 | 2,207,773.00 | 14.09 | 6.01 | 16.80 | 7.60 | 65.94 | 61.95 | 18.11 | 8.44 | 1.35 | 46.81 | 0.0699 | 0.00 | 14.78 | 11.08 | 67.70 | -- | 50.82 | -- |
| Orion Oyj | 20.12bn | 5.33bn | 103.89bn | 4.03k | 19.47 | 7.59 | 17.52 | 5.16 | 3.56 | 3.56 | 13.44 | 9.13 | 1.04 | 1.55 | 6.22 | -- | 27.49 | 21.94 | 35.66 | 27.24 | 64.20 | 60.82 | 26.47 | 22.71 | 1.58 | 161.95 | 0.1921 | 72.07 | 22.50 | 11.88 | 51.65 | 17.87 | 19.12 | 3.71 |
| Swedish Orphan Biovitrum AB (publ) | 28.24bn | 478.00m | 150.47bn | 1.89k | 324.64 | 3.86 | 38.00 | 5.33 | 1.30 | 1.30 | 81.42 | 109.12 | 0.3953 | 1.28 | 5.11 | 14,956,040.00 | 0.6663 | 3.92 | 0.8337 | 5.04 | 78.89 | 77.84 | 1.69 | 10.91 | 0.585 | 9.61 | 0.2336 | 0.00 | 8.50 | 13.10 | -87.70 | -31.82 | -3.93 | -- |
Data as of Feb 19 2026. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
22.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Apr 2025 | 2.81m | 4.69% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 2.30m | 3.85% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 1.52m | 2.54% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.46m | 2.44% |
| Carnegie Fonder ABas of 30 Dec 2025 | 1.30m | 2.18% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 1.23m | 2.05% |
| AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 30 Apr 2025 | 783.69k | 1.31% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 31 Jan 2026 | 771.22k | 1.29% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 767.12k | 1.28% |
| Devon Equity Management Ltd.as of 31 Jan 2026 | 691.82k | 1.16% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
